Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside

Fleurence, Julien; Bahri, M.; Fougeray, Sophie; Faraj, Sébastien; Vermeulen, Sarah; Pinault, Émilie; Geraldo, Fanny; Oliver, Lisa; Véziers, Joëlle; Marquet, Pierre; Rabé, Marion; Gratas, Catherine; M. Vallette, François; Pecqueur, Claire; Paris, François; Birklé, Stéphane

doi:10.1002/ijc.32533

Public

Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside

Published in International Journal of Cancer • Jun 26, 2019

Authors:

Julien Fleurence

M. Bahri

Sophie Fougeray

Abstract

Stem cell chemoresistance remains challenging the efficacy of the front-line temozolomide against glioblastoma. Novel therapies are urgently needed to fight those cells in order to control tumor relapse. Here, we report that anti-O-acetyl-GD2 adjuvant immunotherapy controls glioma stem-like cell-dri...

Subject

Temozolomide

Adjuvant

Glioma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!